News and analysis on diagnostic technologies and applications.
The partners inked a licensing deal to market and distribute TGen's DeepChek-TB as a compact, portable, and affordable diagnostic model for physician use.
The deal will enable the Australian firm to distribute its diagnostic tests in the United Arab Emirates, Saudi Arabia, Bahrain, Qatar, and Oman.
UBS granted Agilent a Buy rating and a $92 price target, and Qiagen a Neutral rating with a $42 price target.
DermTech develops diagnostics for skin cancer and other skin diseases, and provides molecular pathology services through its CLIA-certified lab.
The researchers developed a plasma protein signature that can identify patients with cerebrospinal fluid amyloid-β42 levels indicative of risk for the disease.
